BioNTech SE

BNTX

NASDAQ. Currency in USD

134.00 -0.89 ( -0.65% )

Real time prices: October 03

Market Cap.
32.73B
Beta (5Y monthly)
0.03
Price/Earnings
2.51
EPS (TTM)
51.78
Forward Dividend
2.11 (1.62%)
Ex-Dividend Date
Jun 03, 2022
Volume
735,183
1y Target Est.
296.81
Day's Range
133.03
-
136.25
52 Week's Range
117.08
-
374.58

Historical Summary

Performance
EPS growth
Share Buybacks

About BioNTech SE

Sector
Healthcare
Industry
Biotechnology
Website
https://www.biontech.de
Exchange
NASDAQ (XNAS)
Shares Outstanding
246.81M
Employees
3082
Address
An der Goldgrube 12, Mainz, Germany, 55131
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Latest news

1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds
1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds

A Kaiser Family Foundation survey found that about half of Americans have heard little or...
By MarketWatch - 2 days ago

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222,...
By Zacks Investment Research - 3 days ago

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids
Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent...
By Zacks Investment Research - 3 days ago

Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions
Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions

The Canadian government announced Monday it will no longer require people to wear masks on...
By MarketWatch - 4 days ago

Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids
Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids

Pfizer (PFE) and partner BioNTech seek authorization from the FDA for using their bivalent COVID-19...
By Zacks Investment Research - 5 days ago

Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions
Canada to scrap mask mandate on planes, joining Japan, Hong Kong and U.A.E. in lifting COVID restrictions

The Canadian government announced Monday it will no longer require people to wear masks on...
By MarketWatch - 5 days ago

Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11

Pfizer and German partner BioNTech said Monday they're seeking Food and Drug Administration authorization for...
By MarketWatch - 5 days ago

Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11

Pfizer and German partner BioNTech said Monday they're seeking Food and Drug Administration authorization for...
By MarketWatch - 6 days ago